Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy

Dose-Dense Primary Chemotherapy, as Part of Multidisciplinary Treatment, for Inoperable Stage III B Breast Cancer – Long-Term Results of a Phase II Trial

“…Our results are comparable with those of Clouth et al [38] and McIntosh et al [15], who reported 10 and 7%, respectively, of local recurrences in the chest wall after mastectomy in LABC patients treated with sequential anthra-taxane-based chemotherapy and anthra-based combination, respectively. It is worth noting that in our study all 3 patients refused RT.…”

“…The excellent long-term local and distant control achieved in this patient allow us to maintain hope for women to preserve their breast even with locally advanced disease. Several authors have reported unacceptably high local-regional and ipsilateral breast tumor recurrence rates and poorer OS in LABC patients, not primarily eligible for conservative treatment, who underwent BCT after primary chemotherapy (LRR rate up to 28%) [12, 13], suggesting some differences between de novo BCT and BCT following primary chemotherapy.In contrast to these reports, other studies reported satisfactory local (≤5%) and distant control in LABC downstaged with primary chemotherapy [12, 14, 15], by adopting careful patient selection, as for patients with early breast cancer treated by breast conservation without initial primary chemotherapy. In our study, overall BCT patients had a clinical response >50%, residual tumor size ≤3 cm as a solitary lesion, negative resection margins and resolution of skin and/or chest wall involvement and radiation.…”

“…breast-conserving therapy (BCT), remains a great challenge for both oncologists and surgeons [9,10,11,12] because of concerns about unacceptably high local failure rates reported by several studies [12, 13]. In contrast to these reports, other studies reported satisfactory local and distant control in LABC downstaged with primary chemotherapy [12, 14, 15]. In summary, local-regional relapse (LRR) rates ranged from 1 to 28% [12], but most studies included small numbers of patients with T4 disease, together with other LABC, such as T2 and T3 or any T-N 2–3 , thus making interpretation of the data difficult.…”

Neo-adjuvant chemotherapy and the recurrence of breast cancer in a tertiary care rural hospital of West Bengal, India

“…10 Hung WK et al, Stuart A McIntosh et al Poole GV et al also showed the same response in their studies. [23][24][25] All the 16 LABC patients who had recurrence in the present study received full course of NACT treatment and achieved complete pathological response after it. Nevertheless their average recurrence free survival was 2.8 years.…”

Triple negative phenotype and N‐ratio are important for prognosis in patients with stage IIIB non‐inflammatory breast carcinoma

“…Therefore, pCR without any residual tumor in both breast and axillary lymph nodes after neoadjuvant chemotherapy is strong independent predictor of improved survival [24][25][26]. The studies in the literature showed that the rates of pCR have been much lower and have generally been less than 20% [27][28][29]. More recently, the use of taxanes in chemotherapy regimens has allowed a pCR rate of up to 34% [27,30], although a study indicated that the addition of taxanes to chemotherapy regimen obtained a marginal improvement to their pCR rate from 18% to 19.8% [28].…”